Business Context and Reporting Period
This Form 8-K Current Report was filed by Illumina, Inc. on May 14, 2006. The filing discloses the entry into a material definitive agreement with deCODE genetics, ehf. (deCODE) to collaborate on the development and commercialization of specific diagnostic tests.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of a new strategic partnership.
Material Changes and Agreements
On May 14, 2006, Illumina and deCODE executed a Joint Development and Licensing Agreement. Key terms include:
- Scope: Exclusive collaboration to develop, validate, and commercialize diagnostic tests for gene variants linked to heart attack (leukotriene A4 hydrolase), type 2 diabetes (TCF7L2), and breast cancer (BARD1).
- Platform: Tests are intended for use on Illumina's BeadXpress system, expected to launch later in 2006.
- Roles: Illumina is responsible for manufacturing, marketing, and selling the products.
- Financial Structure: Parties will share development costs and split profits from sales.
- Supply Agreement: A separate agreement allows Illumina to install instrumentation at deCODE for whole genome association studies on up to 100,000 samples using HumanHap300 BeadChips.
- Termination: The agreement may be terminated for specific products if funding is discontinued, or in whole for material breach, bankruptcy, or insolvency.
Guidance, Outlook, and Risks
The filing indicates an expectation that the BeadXpress system will be launched later in the year. The full text of the Development Agreement is not included in this report but is expected to be filed as an exhibit to the next quarterly report on Form 10-Q. No specific financial guidance or risk factors beyond standard termination clauses were detailed in this text.
Investor Verification Checklist
- Verify the launch timeline and market readiness of the BeadXpress system.
- Review the full Development Agreement in the upcoming Form 10-Q for detailed profit-sharing percentages and cost allocation.
- Assess the clinical validation status of the diagnostic tests for the three targeted disease pathways.
- Monitor the progress of the 100,000-sample whole genome association study at deCODE.